Favipiravir

Base Information Edit

Chemical Name:Favipiravir
CAS No.:259793-96-9
Molecular Formula:C5H4FN3O2
Molecular Weight:157.104
Hs Code.:2934999090
European Community (EC) Number:856-840-0
UNII:EW5GL2X7E0
DSSTox Substance ID:DTXSID60948878
Nikkaji Number:J1.636.682J
Wikipedia:Favipiravir
Wikidata:Q16934561
NCI Thesaurus Code:C81605
Metabolomics Workbench ID:144533
ChEMBL ID:CHEMBL221722
Mol file:259793-96-9.mol

Synonyms:6-fluoro-3-hydroxy-2-pyrazinecarboxamide;Avigan;FabiFlu;favipiravir;T-705 cpd

Suppliers and Price of Favipiravir

Supply Marketing:Edit

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

Usbiological
Favipiravir
10mg
$ 319.00

TRC
Favipiravir
250mg
$ 300.00

TRC
Favipiravir
25mg
$ 85.00

TRC
Favipiravir
100mg
$ 150.00

Tocris
Favipiravir ≥98%(HPLC)
50
$ 135.00

Medical Isotopes, Inc.
Favipiravir
10 mg
$ 625.00

Medical Isotopes, Inc.
Favipiravir
100 mg
$ 2000.00

DC Chemicals
Favipiravir(T-705) >98%
1 g
$ 1200.00

DC Chemicals
Favipiravir(T-705) >98%
100 mg
$ 350.00

ChemScene
Favipiravir 99.98%
10g
$ 55.00

Total 165 raw suppliers

Chemical Property of Favipiravir Edit

Chemical Property:

Boiling Point:552.6 °C at 760 mmHg
PKA:8.77±0.60(Predicted)
Flash Point:288 °C
PSA：88.84000
Density:1.78 g/cm³
LogP:-0.29180
Storage Temp.:under inert gas (nitrogen or Argon) at 2-8°C
Solubility.:Soluble in DMSO (30 mg/mL), water (12 mg/mL with warming)
XLogP3:-0.6
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:4
Rotatable Bond Count:1
Exact Mass:157.02875454
Heavy Atom Count:11
Complexity:282

Purity/Quality:

99%+ ^*data from raw suppliers

Favipiravir ^*data from reagent suppliers

Safty Information:

Pictogram(s):
Hazard Codes:

MSDS Files:: SDS file from LookChem

Useful:

Canonical SMILES:C1=C(N=C(C(=O)N1)C(=O)N)F
Recent ClinicalTrials:Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19
Recent EU Clinical Trials:A Phase 3, Multicenter, Prospective, Placebo-Controlled, Randomized, Double-Blind Study to Assess the Efficacy and Safety of Favipiravir in Non-critical Hospitalized Patients with COVID-19 Pneumonia (PROVIR)
Recent NIPH Clinical Trials:Single Ascending-dose Study of Injectable Favipiravir
Description Favipiravir, 6-fluoro-3-hydroxypyrazine-2-carboxamide, is a new broad-spectrum antiviral drug targeting RNA-dependent RNA polymerase (RdRp) developed by Japan's Toyama Chemical Pharmaceutical Company. It was approved for marketing in Japan in March 2014 for the treatment of new and recurrent influenza. During the outbreak of the new coronavirus, the results of the Phase I clinical study of the drug published in March 2020 showed that the drug may have the effect of speeding up virus clearance to alleviate the progress of new coronavirus pneumonia.
Uses Favipiravir is used for the treatment of advanced Ebola virus infection in a small animal model. It suppressed the replication of Zaire Ebola virus and prevented a lethal outcome in 100% of the animals. Based on the studies, Favipiravir can be a candidate for the treatment of Ebola hemorrhagic fever. Favipiravir can be used for antiviral treatment of influenza A and B. Studies have shown that in addition to influenza virus, the drug also exhibits good antiviral activity against a variety of RNA viruses, such as Ebola virus, arena virus, Bunia virus, rabies virus and now COVID-19.

Technology Process of Favipiravir

There total 45 articles about Favipiravir which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 92.3%

: 356783-31-8
6-fluoro-3-hydroxypyrazine-2-carbonitrile

: 259793-96-9
favipiravir

Guidance literature:: 6-fluoro-3-hydroxypyrazine-2-carbonitrile; With sulfuric acid; at 50 ℃; for 4h;

With water; at 3 - 10 ℃; for 0.666667h;

With sodium hydroxide; In water; at 10 ℃; for 0.75h;